BACKGROUND: Human metapneumovirus (HMPV) causes acute respiratory tract infections in infants and children. We sought to measure the clinical and economic burden of HMPV infection in hospitalized children. METHODS: We conducted a retrospective cohort study from 2007 to 2013 at Primary Children's Hospital in Salt Lake City, Utah. Children <18 years of age with laboratory-confirmed HMPV infection were included. Demographic, clinical, and financial data were abstracted from the electronic medical record. RESULTS: During the study period, 815 children were hospitalized with laboratory-confirmed HMPV infection: 16% <6 months, 50% 6-23 months, 23% 2-4 years, and 11% 5-17 years of age. A complex chronic condition was identified in 453 (56%) children hospitalized with HMPV infection; this proportion increased with increasing age (P < .001). There was marked variation in annual HMPV hospitalization rates, ranging from 9 of 100 000 person-years in 2012-2013 to 79 of 100 000 in 2009-2010. Hospitalization rates were highest among children <2 years (200 of 100 000 person-years) and lowest among children 5-17 years of age (5 of 100 000). Of hospitalized children, 18% were treated in the intensive care unit and 6% required mechanical ventilation. The median length of stay was 2.8 days (interquartile range [IQR], 1.8-4.6) and did not vary by age. The median total hospital cost per patient was $5513 (IQR, $3850-$9946) with significantly higher costs for patients with chronic medical conditions (P < .001). CONCLUSIONS: Human metapneumovirus infection results in a large number of hospitalizations with substantial morbidity, resource utilization, and costs. The development of a safe and effective vaccine could reduce the clinical and economic burden of HMPV.
BACKGROUND:Human metapneumovirus (HMPV) causes acute respiratory tract infections in infants and children. We sought to measure the clinical and economic burden of HMPV infection in hospitalized children. METHODS: We conducted a retrospective cohort study from 2007 to 2013 at Primary Children's Hospital in Salt Lake City, Utah. Children <18 years of age with laboratory-confirmed HMPV infection were included. Demographic, clinical, and financial data were abstracted from the electronic medical record. RESULTS: During the study period, 815 children were hospitalized with laboratory-confirmed HMPV infection: 16% <6 months, 50% 6-23 months, 23% 2-4 years, and 11% 5-17 years of age. A complex chronic condition was identified in 453 (56%) children hospitalized with HMPV infection; this proportion increased with increasing age (P < .001). There was marked variation in annual HMPV hospitalization rates, ranging from 9 of 100 000 person-years in 2012-2013 to 79 of 100 000 in 2009-2010. Hospitalization rates were highest among children <2 years (200 of 100 000 person-years) and lowest among children 5-17 years of age (5 of 100 000). Of hospitalized children, 18% were treated in the intensive care unit and 6% required mechanical ventilation. The median length of stay was 2.8 days (interquartile range [IQR], 1.8-4.6) and did not vary by age. The median total hospital cost per patient was $5513 (IQR, $3850-$9946) with significantly higher costs for patients with chronic medical conditions (P < .001). CONCLUSIONS:Human metapneumovirus infection results in a large number of hospitalizations with substantial morbidity, resource utilization, and costs. The development of a safe and effective vaccine could reduce the clinical and economic burden of HMPV.
Authors: Fatimah S Dawood; Sandra S Chaves; Alejandro Pérez; Arthur Reingold; James Meek; Monica M Farley; Patricia Ryan; Ruth Lynfield; Craig Morin; Joan Baumbach; Nancy M Bennett; Shelley Zansky; Ann Thomas; Mary Lou Lindegren; William Schaffner; Lyn Finelli Journal: J Infect Dis Date: 2013-08-28 Impact factor: 5.226
Authors: José Ordás; José Antonio Boga; Marta Alvarez-Argüelles; Laura Villa; Cristina Rodríguez-Dehli; María de Oña; Julián Rodríguez; Santiago Melón Journal: J Clin Microbiol Date: 2006-08 Impact factor: 5.948
Authors: Katherine A Poehling; Kathryn M Edwards; Marie R Griffin; Peter G Szilagyi; Mary A Staat; Marika K Iwane; Beverly M Snively; Cynthia K Suerken; Caroline B Hall; Geoffrey A Weinberg; Sandra S Chaves; Yuwei Zhu; Monica M McNeal; Carolyn B Bridges Journal: Pediatrics Date: 2013-01-06 Impact factor: 7.124
Authors: Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Caroline B Hall; Peter G Szilagyi; Mary A Staat; Marika Iwane; Mila M Prill; John V Williams Journal: N Engl J Med Date: 2013-02-14 Impact factor: 91.245
Authors: B G van den Hoogen; J C de Jong; J Groen; T Kuiken; R de Groot; R A Fouchier; A D Osterhaus Journal: Nat Med Date: 2001-06 Impact factor: 53.440
Authors: Guillaume B E Stewart-Jones; Jason Gorman; Li Ou; Baoshan Zhang; M Gordon Joyce; Lijuan Yang; Cheng Cheng; Gwo-Yu Chuang; Kathryn E Foulds; Wing-Pui Kong; Adam S Olia; Mallika Sastry; Chen-Hsiang Shen; John-Paul Todd; Yaroslav Tsybovsky; Raffaello Verardi; Yongping Yang; Peter L Collins; Davide Corti; Antonio Lanzavecchia; Diana G Scorpio; John R Mascola; Ursula J Buchholz; Peter D Kwong Journal: Proc Natl Acad Sci U S A Date: 2021-09-28 Impact factor: 11.205
Authors: Annelies Van Den Bergh; Patrice Guillon; Mark von Itzstein; Benjamin Bailly; Larissa Dirr Journal: Antimicrob Agents Chemother Date: 2022-09-12 Impact factor: 5.938
Authors: Leigh M Howard; Kathryn M Edwards; Yuwei Zhu; Marie R Griffin; Geoffrey A Weinberg; Peter G Szilagyi; Mary A Staat; Daniel C Payne; John V Williams Journal: J Pediatric Infect Dis Soc Date: 2018-05-15 Impact factor: 3.164
Authors: Catalina A Andrade; Gaspar A Pacheco; Nicolas M S Gálvez; Jorge A Soto; Susan M Bueno; Alexis M Kalergis Journal: Viruses Date: 2020-06-12 Impact factor: 5.048